Dr. Prince is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
401 North Broadway Street
Weinberg BLDG
Baltimore, MD 21287Phone+1 410-955-8964Fax+1 410-367-2194
Education & Training
State University of New York Downstate Medical Center College of MedicineClass of 2007
Certifications & Licensure
MD State Medical License 2011 - 2025
DC State Medical License 2023 - 2024
VA State Medical License 2023 - 2024
NY State Medical License 2009 - 2012
Publications & Presentations
PubMed
- 5 citationsFinal phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.Courtney D DiNardo, Gail J Roboz, Justin M Watts, Yazan F Madanat, Gabrielle T Prince
Blood Advances. 2024-08-13 - 5 citationsOutcome heterogeneity of-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation.Sergiu Pasca, Saurav D Haldar, Alexander Ambinder, Jonathan A Webster, Tania Jain
Haematologica. 2024-03-01 - 4 citationsVenetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.Khaled Sanber, Kevin Ye, Hua-Ling Tsai, Matthew Newman, Jonathan A Webster
Leukemia & Lymphoma. 2023-04-01
Abstracts/Posters
- Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume LeukapheresisGabrielle T. Prince, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion StudyGabrielle T. Prince, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...Gabrielle T. Prince, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Other Languages
- Spanish, Hebrew
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
